Research programme: staphylococcal infection therapy - Elusys Therapeutics

Drug Profile

Research programme: staphylococcal infection therapy - Elusys Therapeutics

Alternative Names: ETI-211; Staph aureus HP antibody

Latest Information Update: 14 Sep 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Elusys Therapeutics
  • Developer Elusys Therapeutics; Pfizer
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections

Most Recent Events

  • 14 Sep 2010 This programme is still in active development
  • 04 Jan 2007 Elusys Therapeutics and Pfizer agree to co-develop therapies utilising Elusys' HP Antibody™ technology, including ETI 211, for select infectious diseases
  • 02 Feb 2006 Preclinical trials in Meticillin-resistant Staphylococcus aureus infections in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top